Dermapharm Holding SE — subsidiary axicorp GmbH breaks ground for new building near Frankfurt am Main
Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, is starting the construction of a state-of-the-art production, warehouse and administration building at the Friedrichsdorf site at its subsidiary axicorp GmbH.
With the symbolic groundbreaking ceremony, Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE and managing director of axicorp, and Anna-Karina Gerner, managing director of axicorp, carried out the official construction work together with the mayor of the town, Horst Burghardt. The approximately 10,000 m² new building will replace the usable space previously rented on a commercial property of 17,488 m². In addition to the associated optimization of the cost structure, Dermapharm wants to achieve a significant improvement in processes with the new building. Dermapharm is planning an investment volume of approx. € 13 million. Completion of the building is planned for December 2021.
“We see the construction of the ultra-modern building complex as a major milestone in our company history, which is important for the further positive development at the Friedrichsdorf location,” says Managing Director Anna-Karina Gerner. “In addition to the possibility of further growth, the expansion of production and storage capacities essentially serves to optimize processes. Thanks to the new spatial conditions, all processes — from incoming goods to packaging and shipping — can be linked more efficiently with one another and ideally aligned with the production flow, ”emphasizes Gerner. “The optimized infrastructure of the premises as well as larger narcotics safes make it possible to meet the increasing demand for increasingly relevant medicinal products such as medicinal cannabis. This enables us
Health is a matter of trust — the architecture of the building complex was also aligned with this motto, which reflects the corporate culture of axicorp. The light-flooded and spacious new building will offer around 300 employees a modern working environment with ergonomic workplaces.
Axicorp has been based in Friedrichsdorf near Frankfurt am Main for 14 years and has since developed into one of Germany’s leading providers in the field of parallel and re-import of EU pharmaceuticals. The company is also demonstrating dynamic growth as a manufacturer of OTC products made in Germany and has been a successful distributor of medicinal cannabis since 2019. In the parallel import business segment, which includes the business of axicorp, Dermapharm achieved sales of € 244 million in 2019.
